Newswise — The advocacy group Us Against Alzheimer’s (UsA2) did not reveal in its January 19 letter to the FDA urging approval of aducanumab for Alzheimer’s disease it had received monies from the drug’s maker, Biogen, says Leslie Norins, MD, PhD, CEO of Alzheimer’s Germ Quest.
For example, Biogen and its co-venturer, Esai, were both listed as “Premier” sponsors of the virtual Alzheimer’s symposium presented by UsA2 in November 2020. The “premier” designation was ranked even higher than “platinum”, but its cost was not given.
This is similar veiling to that of the Alzheimer’s Association letter supporting approval of the same drug; significant contributions—possibly millions of dollars–to the association from Biogen and Esai were not disclosed, says Dr. Norins.
Although aducanumab is…
